Kilpatrick Townsend managed the global License, Development and Commercialization Agreement between Biotest AG (Biotest), a German publicly traded biotechnology company, and Abbott Laboratories (Abbott) for the further development and commercialization of Biotest’s BT-061, a novel anti-CD4 antibody for the treatment of rheumatoid arthritis (RA) and psoriasis. In connection with the deal, Biotest will receive an upfront payment of $85 million. Additional milestone payments total $395 million, and Biotest will receive royalties thereafter on the sale of commercial products, bringing the total value of the deal well over $500 million.

BT-061 is currently in Phase II clinical trials for Rheumatoid Arthritis (RA) and psoriasis, with pre-clinical studies underway to study its potential use in other immune-related diseases. CD4 is expressed on T-cells and is involved in T-cell mediated modulation of immune responses. BT-061 is a humanized monoclonal antibody that works by activating the body’s T-regulatory cells, a subset of T-cells, strengthening a natural function of the body that prevents excessive immune reactions. Unlike other anti-CD4 antibodies that have been in development, BT-061 does not cause depletion of CD4 positive T-cells that would give rise to weakened immune responses.

Under the terms of the agreement, Abbott and Biotest will co-promote BT-061 in five major European markets (Germany, France, the United Kingdom, Italy and Spain). Abbott will have exclusive global rights to commercialize BT-061 outside those countries. In addition to the upfront fee of $85 million, and subject to achievement of certain development, regulatory, commercial and sales-based milestones, Biotest would be eligible to receive additional milestone payments from Abbott, potentially amounting to a total of $395 million, and royalties. Biotest will be responsible for the manufacture of initial clinical supply of BT-061, and the parties will share responsibility for commercial production.

Experience Center

Match our Experience to Your Needs

View All Case Studies

Experience Highlights

Hovis et al. v. Carboline Company et al.
Successfully defended E. I. du Pont de Nemours and Company in a toxic tort action claiming personal injury allegedly caused by exposure to trace more
Race discrimination class action for one of the largest U.S. forest product manufacturers
Represented one of the largest U.S. forest products manufacturers in a suit brought against our client in Alabama Federal court by the EEOC on behalf more
Brownfields Agreement for property redevelopment for clothing manufacturer
Represented manufacturer as the developer in negotiations with the NC Department of Environment and Natural Resources to obtain a Brownfields more
Economic development of PRA International
Represented PRA International, a leading global clinical research organization, in its headquarters relocation to Raleigh, including negotiating more